GlassScriptPhysician profile
Chau Vu
NPI 1689671497
$4,313.44
in general payments reported to CMS, 2019-2025
25 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.90 · 2020: $236 · 2021: $255 · 2022: $1,635 · 2023: $1,446 · 2024: $401 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.78 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $1,733.72 | 2022-2023 | Painteq |
| Mallinckrodt Hospital Products INC. | $477.32 | 2020-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $370.36 | 2021-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $301.77 | 2023-2025 | Proclaim, Eterna |
| Dermavant Sciences, INC. | $241.87 | 2024 | Vtama |
| Horizon Therapeutics Plc | $191.07 | 2021-2023 | Krystexxa |
| Nevro Corp. | $145.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.08 | 2022-2023 | |
| Almirall LLC | $96.63 | 2021-2022 | |
| Amgen INC. | $85.27 | 2019-2025 | Tavneos |
| Organon LLC | $79.67 | 2025 | Vtama |
| Otsuka America Pharmaceutical, INC. | $64.42 | 2021-2023 | Jynarque |
| Akebia Therapeutics INC | $47.70 | 2024 | Vafseo |
| Epi Health, LLC | $47.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.44 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $44.57 | 2023-2024 | |
| Lilly USA, LLC | $39.25 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.25 | 2022 | |
| Leo Pharma INC. | $25.56 | 2025 | Adbry |
| Opko Pharmaceuticals, LLC | $23.35 | 2021 | |
| Vifor Pharma, INC. | $19.00 | 2023 | Veltassa |
| Arcutis Biotherapeutics, INC. | $18.37 | 2024 | Zoryve |
| Calliditas Therapeutics US INC. | $18.04 | 2022 | |
| Novo Nordisk INC | $16.15 | 2024 | |
| Allergan, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chau Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.